Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Systemic Amyloidosis

Interventions

DRUG

Bortezomib

Bortezomib 1.3mg/m2 sc weekly

DRUG

Pomalidomide

4mg per day taken orally on 1-21 of repeated 28-day cycles

DRUG

Dexamethasone

Dexamethasone 20mg-40mg weekly

Trial Locations (1)

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Jin Lu, MD

OTHER